Cargando…
Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy
BACKGROUND: The use of novel drug agents in the treatment of multiple myeloma (MM) has been associated with improved therapeutic outcomes and survival; however, MM continues to pose a significant economic burden on patients and health care systems. Evaluating economic implications of therapies can p...
Autores principales: | Merola, David, Yong, Candice, Noga, Stephen J., Shermock, Kenneth M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397991/ https://www.ncbi.nlm.nih.gov/pubmed/30247101 http://dx.doi.org/10.18553/jmcp.2018.24.10.1019 |
Ejemplares similares
-
Closed-Loop Medication Management with an Electronic Health Record System in U.S. and Finnish Hospitals
por: Shermock, Susan B., et al.
Publicado: (2023) -
The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016) -
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017) -
Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019) -
Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
por: Fang, Michael, et al.
Publicado: (2021)